Analyzing Covetrus Share Price Over the Last Decade

Is IBEX A Buy?

Forecast by Analysts According to 11 analysts, IBEX stock has an average rating of “Buy” and a 12-month price target of $26.93, up 3.14 percent from the most recent price.

Is Nice Stock A Buy?

Based on 7 buy ratings, 1 hold rating, and no sell ratings, the consensus rating for NICE is Buy, with an average rating score of 2.88.

Is Covetrus A Good Stock To Buy?

In the past year, six Wall Street research analysts have given Covetrus “buy,” “hold,” and “sell” ratings; there is currently one sell rating and five hold ratings for the stock. Investors should “hold” CVET shares, according to the consensus among Wall Street research analysts.

Is Covetrus A Public Company?

According to the 2022 Mainebiz Book of Lists, Covetrus is the largest public company based in Maine by revenues, with approximately 1,000 employees in Portland, where a brand-new, 170,000-square-foot corporate headquarters is nearing completion.

Is Covetrus A Buy?

Consensus Rating: Covetrus has been given a consensus rating of Hold, with an average rating score of 1.83 based on five hold ratings, one sell rating, and no buy ratings.

How Much Is Covetrus Worth?

Covetrus has a market cap of $2.94 billion as of January 2023, making it the world’s 3230th most valuable company by market cap, according to our data.

Is Covetrus Profitable?

Covetrus, Inc. is a company that provides animal health technology and services through its subsidiaries. The company has earnings per share (EPS) of $0.093, gross margin of 18.97%, net profit margin of 0.28 percent, and debt to equity ratio of 68.7 percent.